In the company’s news Friday,
EpiCept Corporation announced third quarter and year-to-date operating and financial results. Figures show a significant reduction in stated loss as the company continues its push to move products into the marketplace.
EpiCept showed a 19% improvement in third quarter figures, posting a net loss of $6.2 million compared to a net loss of $7.7 million for the same quarter last year. For the nine months ending September 30, the company posted a loss of $20.0 million, compared to $22.4 million for the same period last year, a 10% improvement.
EpiCept President and CEO, Jack Talley, commented on the company’s recent accomplishments and goals. “During the third quarter and subsequently, we were acutely focused on securing European regulatory approval for Ceplene®. We were delighted when our efforts proved to be successful with a final, favorable outcome announced last month. We have carefully controlled expenses this year in all areas of company operations.”
“Having secured European approval of Ceplene, the next key item has been advancing partnership dialogues for Ceplene marketing rights and preparing for a commercial launch as soon as possible in 2009. We have also continued our studies with NP-1, our neuropathic pain compound, which we expect to report top-line results by the first quarter of 2009 and the development of EPC2407, our vascular disruption agent for the treatment of cancer,” he continued.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.
To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
